摘要
心房颤动是常见的心律失常之一,可导致卒中,且心房颤动相关卒中的危害严重。口服华法林是预防心房颤动患者发生卒中的有效措施,但华法林治疗窗窄,且易与多种食物、药物发生相互作用。新型口服抗凝药(达比加群酯、利伐沙班、阿哌沙班、依度沙班、贝曲西班)克服了华法林的一些缺点,且能更好地降低心房颤动患者卒中及出血风险,有望成为临床预防心房颤动患者卒中事件的新选择。
Atrial fibrillation is one kind of common arrhythmia, may cause stroke, and atrial fibrillation associated stroke can lead to severe consequences. Oral warfarin is an effective measure to prevent stroke in patients with atrial fibrillation, but its therapeutic window is narrow, is easy to interact with a variety of foods and drugs. New oral anticoagulants including dabigatran etexilate, rivaroxaban, apixaban, edoxaban, betrixaban overcome many shortcomings of warfarrin, have better effect on reducing the risk of stroke and hemorrhage in patients with atrial fibrillation, is possible to become the new choice for clinical prevention of stroke in patients with atrial fibrillation.
出处
《实用心脑肺血管病杂志》
2015年第8期1-4,共4页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
